You are here

Home > Investor Relations

Investor Relations

Featured Event
May 2, 2013
4:30 PM ET 		OncoGenex First Quarter 2013 Conference Call
Webcast Listen to webcast

OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.

View Corporate Fact Sheet

View Product Pipeline

Role of Hsp27 and OGX-427 Mechanism of Action Video

 

Stock quote (NASDAQ: OGXI)
Price: 10.50    Change: + 0.08    Volume 84,500
4:00 PM ET on May 17, 2013
Delayed at least 20 minutes. Provided by eSignal.

Investor Relations Contact
Susan W. Specht
Director, Investor Relations
Phone: 425-686-1535
Email: sspecht@oncogenex.com
Recent Releases
See All
May 2, 2013
OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Program Overview and Reports Financial Results for First Quarter 2013 Download Add to Briefcase
May 1, 2013
OncoGenex Announces Plans for the Initiation of the Rainier™ Clinical Trial Evaluating OGX-427 in Combination with ABRAXANE® plus Gemcitabine in Patients with Metastatic Pancreatic Cancer Download Add to Briefcase
Apr 30, 2013
OncoGenex Announces that the Borealis-2™ Clinical Trial of OGX-427 in Previously Treated Metastatic Bladder Cancer is now Open for Enrollment Download Add to Briefcase
Webcasts & Presentations
See All
May 2, 2013
4:30 PM ET
OncoGenex First Quarter 2013 Conference Call Listen to webcast
Apr 5, 2013
9:30 AM ET
Future Leaders in the Biotech Industry Conference Listen to webcast View Presentation   1.7 MB   Add to Briefcase
Mar 7, 2013
4:30 PM ET
OncoGenex Fourth Quarter 2012 Conference Call Listen to webcast

For Physicians